EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting
Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its...
Drug
Chongqing Precision Biotechnology’s PCAR-19B Receives CDE Nod for Breakthrough Therapy Designation
The China’s Center for Drug Evaluation (CDE) website has indicated that Chongqing Precision Biotechnology Co.,...
Sichuan Kelun-Biotech’s SKB264 Receives Priority Review Status for TNBC Treatment in China
The China’s Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co.,...
Hinova Pharmaceuticals’ HP518 Receives NMPA Approval for mCRPC Clinical Trial
China-based biopharmaceutical company Hinova Pharmaceuticals (SHA: 688302) has announced that it has received clinical trial...
Sino Biopharmaceutical’s TQG3902 Injection Receives NMPA Approval for Septic Shock Clinical Trial
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biotech company based in China, has announced that...
Sirnaomics’ STP705 Demonstrates Positive Results in Phase I Focal Fat Reduction Study
Sirnaomics Ltd (HKG: 2257) has announced positive safety and efficacy results from a Phase I...
Hainan Poly Pharm Receives FDA Approval for PL002 in Primary Liver Cancer Surgery
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received clinical...
Changchun BCHT Biotechnology Receives NMPA Approval for Anti-Tetanus Monoclonal Antibody Injection
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced that it has received clinical...
Shenzhen Chipscreen Biosciences Gets NMPA Approval for Phase I Study of CS32582 in Psoriasis
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced that it...
Shanghai Henlius Biotech’s HanSiZhuang Shows Positive Results in Phase III ASTRUM-002 Study
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company in China, has unveiled positive...
Luye Pharma Group’s Rivastigmine Patch LY03013 Approved by China’s NMPA for Alzheimer’s Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...
Novartis’ Cosentyx Gains FDA Approval for Hidradenitis Suppurativa Treatment
The US Food and Drug Administration (FDA) has issued regulatory approval for Novartis’ (NYSE: NVS)...
Roche’s Gene Therapy Elevidys Misses Primary Endpoint in DMD Trial
Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) has announced that a Phase III trial for its...
Amgen Reports Q3 2023 Financials: 5% Growth Driven by Volume Expansion
Amgen (NASDAQ: AMGN) has released its Q3 2023 financial results, showcasing a 5% year-on-year (YOY)...
Coherus’s Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment
Coherus Biosciences (NASDAQ: CHRS) executives held an investor conference call on October 30, 2023, to...
Staidson Receives NMPA Approval for Clinical Trial of STSA-1301 in Primary Immune Thrombocytopenia
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that it...
Allist Pharmaceuticals’ Furmonertinib Receives FDA Breakthrough Therapy Designation for NSCLC
Shanghai-based biotech Allist Pharmaceuticals Co., Ltd (SHA: 688578) has announced that it has received breakthrough...
Yirui Pharmaceutical’s YR001 Completes Successful Phase I Clinical Study in the US
Hangzhou-based Yirui Pharmaceutical Technology Co., Ltd has announced the successful conclusion of a Phase I...
CDE Grants Priority Review to LaNova’s LM-302, Roche’s Alectinib, and Alphamab’s KN026
China’s Center for Drug Evaluation (CDE) has indicated that LaNova Medicines’ LM-302, Roche’s (SWX: ROG)...
Boan Biotech Enrolls First Patient in Phase III Study for Opdivo Biosimilar BA1104 in China
Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced the enrollment of...